TTOO stock $0.0001 on NASDAQ 19 Mar 2026 Market Closed: top losers risk

TTOO stock closed the session at $0.0001 on NASDAQ in the United States on 19 Mar 2026, plunging -95.45% for the day. The microcap trade showed volume 35 versus an average of 51,511, highlighting extreme illiquidity. Traders listed T2 Biosystems, Inc. (TTOO) among the market’s top losers at market close. We use Meyka AI’s real-time tools to link the sharp price move to weak financials, low liquidity and historic revenue declines.

TTOO stock snapshot and session data

T2 Biosystems, Inc. (TTOO) closed at $0.0001 on NASDAQ in USD. The session range was $0.0001–$0.0115 and the previous close was $0.0022. Market cap sits at $2,805.00 with shares outstanding 28,045,417. Price averages are 50-day $0.002408 and 200-day $0.026551, showing a steep downtrend.

Recent drivers and company update

T2 Biosystems reported steep top-line pressure with 2023 revenue at $7.19 million, down 67.75% year-over-year. Management’s last public earnings announcement was on 04 Mar 2026, with EPS still negative at -0.03. The weak revenue and prior losses help explain today’s top losers listing and extreme share weakness. For company filings and profile, see the T2 Biosystems website source and aggregated data source.

TTOO stock financials and valuation

Key metrics show large operating losses and limited liquidity. Cash per share is $6.01 and revenue per share TTM is 2.76. Enterprise value is $33,811,805.00 and price-to-sales ratio is 0.00 (rounded). Current ratio is 0.45, and EV-to-sales stands at 4.70, underlining a mismatch between market cap and enterprise value driven by low free float and liabilities.

Technical view and trading signals for TTOO stock

Momentum indicators are weak and volume is thin. RSI reads 44.72 and ADX is 37.99, suggesting a strong trend but in a downward direction. The 50-day average is far above the last trade. Low on-book volume and an average volume of 51,511 versus today’s 35 shares raise execution risk for larger orders.

Meyka AI rates TTOO with a score out of 100 and forecast

Meyka AI rates TTOO with a score out of 100: 66.22 / 100, Grade B, Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, industry metrics, financial growth, key ratios, analyst signals, and forecasts. Meyka AI’s forecast model projects a quarterly value of $2.61, compared with the current price $0.0001, implying an outsized model-based upside of 2,609,900.00%. Monthly model output shows -$0.02, which is non-meaningful at microcap prices. Forecasts are model-based projections and not guarantees.

Risks and catalysts affecting the TTOO stock outlook

Primary risks are severe liquidity constraints, continued operating losses, and potential delisting pressure at the exchange level. Catalysts would include new clinical wins, commercial adoption of the T2Dx platform, or a strategic partnership with a larger diagnostics firm. Given the low current price and tiny daily liquidity, any positive news could move the price sharply, but the reverse is also true.

Final Thoughts

TTOO stock closed the market at $0.0001 on NASDAQ on 19 Mar 2026, marking it among the session’s top losers. Weak 2023 revenue of $7.19 million, a negative EPS of -0.03, and minimal intraday volume of 35 shares explain the sharp drop. Our Meyka AI grade is 66.22 (B, HOLD) and it flags liquidity and balance-sheet stress as the main risks. For scenario planning, realistic near-term price targets are: bear $0.00, base $0.01 (implied +9,900.00% from $0.0001), and bull $0.05 (implied +49,900.00%). Meyka AI’s forecast model projects a quarterly value of $2.61, but that model outcome is highly speculative against current market mechanics. Investors should weigh the company’s diagnostic pipeline and any pending clinical or commercial updates against clear insolvency and trading risks. This analysis uses Meyka AI as an AI-powered market analysis platform and is informational only, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.